Balaji Prasad
Stock Analyst at Barclays
(2.33)
# 1,469
Out of 4,496 analysts
100
Total ratings
40.82%
Success rate
-0.88%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Downgrades: Equal-Weight | $38 → $25 | $19.37 | +29.07% | 5 | Jul 3, 2024 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $23 → $21 | $12.72 | +65.09% | 8 | Jun 28, 2024 | |
| TEVA Teva Pharmaceutical | Maintains: Overweight | $20 → $21 | $16.81 | +24.93% | 8 | Jun 5, 2024 | |
| ALVO Alvotech | Maintains: Overweight | $20 → $22 | $11.94 | +84.25% | 4 | May 24, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $50 → $60 | $27.04 | +121.89% | 3 | May 10, 2024 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $10 → $13 | $18.64 | -30.26% | 6 | May 10, 2024 | |
| RDY Dr. Reddy's Laboratories | Maintains: Overweight | $80 → $81 | $78.12 | +3.69% | 10 | May 8, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $230 → $200 | $109.01 | +83.47% | 4 | May 3, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $655 → $570 | $468.20 | +21.74% | 7 | May 2, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $260 → $230 | $178.58 | +28.79% | 8 | Apr 23, 2024 | |
| RVNC Revance Therapeutics | Maintains: Overweight | $35 → $10 | $3.64 | +175.10% | 7 | Jan 29, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $6 → $8 | $7.24 | +10.50% | 3 | Jan 29, 2024 | |
| EOLS Evolus | Upgrades: Overweight | $10 → $16 | $11.96 | +33.78% | 4 | Jan 29, 2024 | |
| PYPD PolyPid | Maintains: Equal-Weight | $2.5 → $10 | $3.43 | +191.55% | 2 | Oct 23, 2023 | |
| CHRS Coherus BioSciences | Maintains: Overweight | $8 → $7 | $1.64 | +326.83% | 5 | Oct 23, 2023 | |
| OGN Organon & Co. | Initiates: Overweight | $28 | $20.98 | +33.46% | 1 | Sep 21, 2023 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $120 → $110 | $99.76 | +10.26% | 9 | Jul 25, 2023 | |
| VTRS Viatris | Downgrades: Underweight | $11 | $11.84 | -7.09% | 6 | Jun 23, 2023 |
Pacira BioSciences
Jul 3, 2024
Downgrades: Equal-Weight
Price Target: $38 → $25
Current: $19.37
Upside: +29.07%
Elanco Animal Health
Jun 28, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $12.72
Upside: +65.09%
Teva Pharmaceutical
Jun 5, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $16.81
Upside: +24.93%
Alvotech
May 24, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.94
Upside: +84.25%
Tarsus Pharmaceuticals
May 10, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $27.04
Upside: +121.89%
Phibro Animal Health
May 10, 2024
Maintains: Underweight
Price Target: $10 → $13
Current: $18.64
Upside: -30.26%
Dr. Reddy's Laboratories
May 8, 2024
Maintains: Overweight
Price Target: $80 → $81
Current: $78.12
Upside: +3.69%
Jazz Pharmaceuticals
May 3, 2024
Maintains: Overweight
Price Target: $230 → $200
Current: $109.01
Upside: +83.47%
IDEXX Laboratories
May 2, 2024
Maintains: Overweight
Price Target: $655 → $570
Current: $468.20
Upside: +21.74%
Zoetis
Apr 23, 2024
Maintains: Overweight
Price Target: $260 → $230
Current: $178.58
Upside: +28.79%
Revance Therapeutics
Jan 29, 2024
Maintains: Overweight
Price Target: $35 → $10
Current: $3.64
Upside: +175.10%
Amneal Pharmaceuticals
Jan 29, 2024
Maintains: Overweight
Price Target: $6 → $8
Current: $7.24
Upside: +10.50%
Evolus
Jan 29, 2024
Upgrades: Overweight
Price Target: $10 → $16
Current: $11.96
Upside: +33.78%
PolyPid
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.43
Upside: +191.55%
Coherus BioSciences
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.64
Upside: +326.83%
Organon & Co.
Sep 21, 2023
Initiates: Overweight
Price Target: $28
Current: $20.98
Upside: +33.46%
Ligand Pharmaceuticals
Jul 25, 2023
Maintains: Overweight
Price Target: $120 → $110
Current: $99.76
Upside: +10.26%
Viatris
Jun 23, 2023
Downgrades: Underweight
Price Target: $11
Current: $11.84
Upside: -7.09%